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Editorial on the Research Topic
Primary Glial and Immune Cell Pathology in Neurodegenerative Diseases
Non-neuronal cells in the brain have been proposed as key modulators of neuronal network
function in health and in neurological disease. Until recently, the involvement of glial cells—
including astrocytes, microglial cells, oligodendrocytes and their progenitors—and infiltrating
immune cells in neurodegenerative diseases has been merely viewed as a secondary adaptive
response to disease-specific neuronal pathology. It emerges that glial and other non-neuronal cells
can also be directly affected by neurodegenerative cues, worsening neuronal dysfunction (1, 2).
This has highlighted new potential avenues in targeting disease pathways in a broad spectrum
of neurodegenerative conditions, which would require teasing apart primary pathology from
secondary processes in multiple cell types.
In this issue we brought together some of the leaders in glial cell biology and neurodegenerative
disease research to cover recent advances in pathomechanistic studies informing novel
experimental treatment strategies in six review articles.
The Research Topic starts with two articles discussing the emerging role of astrocytes in
neurodegeneration. One of the most argued, and therapeutically relevant issues, is the extent
to which morphological, gene expression and signaling changes characterize a primary cell-
autonomous astrocyte pathology or a secondary adaptive or “reactive” response to damage. There
is a consensus in the field to steer away from the less reliable phenotypic classifications and
rather assess the function of various astrocytic states in individual disease models to help reveal
potential treatment targets (3). What complicates this assessment is the growing evidence that
astrocytes already represent a large and heterogenous cell population (4, 5). Monterey et al.
review the “many faces” of astrocytes, which can represent both a regional cell diversity and
a broad functional spectrum in disease with multiple targetable elements. They discuss recent
advances in sequencing technologies, and how they can be used to distinguish pathological cell
states and signaling disturbances in Alzheimer’s disease (AD). The article by García-Bermúdez
et al. emphasizes that glaucoma, a common eye disease that damages the optic nerve and the
retina, shares glia-mediated mechanisms with many neurodegenerative diseases, such as AD. The
concept of common pathological processes between the eye and the brain is also supported by
observations of retinal changes in AD patients, forming the basis of an emerging ophthalmological
diagnostic opportunity for neurodegenerative disorders (6). Furthermore, the authors provide a
broad overview on retinal glia-ganglion cell interactions as potential therapeutic targets. Altogether,
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these articles highlight the importance of distinguishing
homoeostatic and detrimental astrocyte responses for identifying
potentially targetable pathological signaling cascades.
Another major advance concerns microglial transcriptomic
and inflammatory signaling changes in neurodegenerative
pathologies. Similar to astrocytes, microglia may adapt to
neuronal injuries by regaining their homeostatic function but
can rapidly escalate the expression of inflammatory mediators
as part of the innate immune response. How the adaptive
immune response and other risk factors trigger this process
in neurodegeneration have been an exciting topic in research
over the last decade (7, 8). A minireview by Candlish and
Hefendehl highlight the recent significant advances in this
field. In particular, they overview mechanisms that govern
the transition of microglia into various subtypes during the
neurodegenerative process. A particularly interesting angle is
the discussion about the risks that lifestyle factors and aging
processes impose on cell phenotype changes. Nitsch et al. then
provides a detailed overview on the contribution of microglial
signaling to AD pathology with a specific focus on interleukin-23
(IL-23). This paper sheds light on mechanisms by which p40, an
IL-23 subunit can be released by microglial cells upon exposure
to amyloid-beta (Aβ), a central molecule in AD pathogenesis.
One of the key messages of this review is that p40 appears to
establish a new link betweenAβ and neuroinflammation, possibly
via Th17 cells, astrocytes and microglia. Although the identity
of effector cells and pathways induced by IL-23 require further
elucidation, blocking or neutralizing antibodies for IL-23 may
provide promises in reducing cerebral amyloid load or soluble Aβ
species (9), which may attract therapeutic interests. Since anti-
inflammatory or current antibody treatment approaches have
yet to improve the clinical outcome in neurodegeneration, for
instance in AD patients (10, 11), the articles in this special issue
well serve the purpose of highlighting potential target options for
more effective strategies.
The final two articles wrap up the recently revealed aspects
of interactions between astrocytes, microglia, peripheral immune
cells, and their effect on neuronal networks. Pietrowski et
al. reviews the growing evidence of purinergic signaling and
its breakdown between glial cells and neurons. This is of
particular relevance to non-cell autonomous pathomechanisms
in neurodegeneration (1, 7), which can worsen neuronal network
function, leading to cognitive or motor decline. This paper
also brings up the issue of emerging major transcriptional and
functional differences between human and mouse astrocytes and
microglia (12, 13), including expression of genes that are a
pre-requisite for their interactions with neurons. Considering
these potential differences is crucial when interpreting results in
mouse diseasemodels that do not entirely recapitulate the human
pathobiological phenotype (14). Another timely issue related
to glial cell communication concerns immune cells, a topic
which has emerged onto the central stage of neurodegeneration
research. Copas et al. put this into an interesting perspective.
They describe how the genetic risk in Parkinson’s Disease (PD)
may affect glial cells and conspire with peripheral infections
during lifetime, predisposing to a chronic neuroinflammatory
response. The authors follow us through the ways infiltrating T
cells could play a central role, triggered by antigen-presenting
microglia. They argue that this may also lead to altered astrocytic
inflammatory responses, and consequently contribute to the
loss of dopaminergic neurons. The broad overview of the
above disease-related pathways illuminates the role of infection
and peripheral immune activation as important risk factors in
neurodegenerative diseases.
CONCLUSIONS
Overall, the review articles in this issue remind us of the
multiple cell-types that are primarily involved in disease, and
also focus on those cell populations that are not innate in the
brain. The discussions highlight the need for systems biology
approaches to distinguish initiating molecular disturbances
that can be obscured by secondary homeostatic responses in
many cell populations. Recent examples have already shown
us how new technologies and platforms, such as single
cell or spatial transcriptomics and human stem cell-based
or brain organoids could resolve the above problem (15–
17). We anticipate that the emerging data demonstrating
human-specific differences in pathogenesis will transform
translational science and personalized treatment strategies in
this decade.
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